We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.87B
1-Year Est. Return 205.24%
This Fund
S&P 500
This Quarter Est. Return
-2.69%
1 Year Est. Return
+205.24%
3 Year Est. Return
+440.18%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.09B
AUM Growth
+$407M
Cap. Flow
+$944M
Cap. Flow %
30.56%
Top 10 Hldgs %
53.08%
Holding
79
New
16
Increased
25
Reduced
8
Closed
10

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$94.7M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$86.1M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$83.8M
4
GERN icon
Geron
GERN
+$83.2M
5
TARS icon
Tarsus Pharmaceuticals
TARS
+$73.4M

Top Sells

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$125M
2
HRMY icon
Harmony Biosciences
HRMY
+$49.9M
3
NMRA icon
Neumora Therapeutics
NMRA
+$42.4M
4
GH icon
Guardant Health
GH
+$42.1M
5
GMAB icon
Genmab
GMAB
+$41.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENE icon
26
Xenon Pharmaceuticals
XENE
$5.57B
$33.5M 1.09%
1,000,000
+830,868
+491% +$31.5M
EWTX icon
27
Edgewise Therapeutics
EWTX
$4.84B
$30.8M 1%
1,400,000
+689,579
+97% +$18.1M
MTSR
28
DELISTED
Metsera Inc
MTSR
$29.8M 0.96%
+1,094,408
New +$31M
PCVX icon
29
Vaxcyte
PCVX
$8.9B
$28.3M 0.92%
+750,000
New +$60M
AUTL
30
Autolus Therapeutics
AUTL
$516M
$27.7M 0.9%
17,849,482
+3,630,579
+26% +$7.37M
BCAX
31
Bicara Therapeutics
BCAX
$1.49B
$26.1M 0.84%
2,000,000
– –
CMPS
32
Compass Pathways
CMPS
$1.96B
$25.3M 0.82%
+8,859,648
New +$34M
TECX
33
Tectonic Therapeutic
TECX
$561M
$24.8M 0.8%
+1,401,938
New +$45.7M
ABVX
34
Abivax
ABVX
$9.12B
$22.4M 0.72%
3,579,209
– –
MBX
35
MBX Biosciences
MBX
$2.92B
$22.3M 0.72%
3,018,935
– –
GHRS icon
36
GH Research
GHRS
$1.9B
$22.1M 0.71%
+2,000,000
New +$22.4M
DYN icon
37
Dyne Therapeutics
DYN
$3.37B
$20.9M 0.68%
2,000,000
– –
ENGN icon
38
enGene Therapeutics
ENGN
$127M
$20.4M 0.66%
4,557,575
– –
INSM icon
39
Insmed
INSM
$26.9B
$19.4M 0.63%
+254,751
New +$19.5M
LKFT
40
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
$18.6M 0.6%
741,068
-39,710
-5% -$1M
SAGE
41
DELISTED
Sage Therapeutics
SAGE
$16.2M 0.52%
+2,038,845
New +$14.9M
TERN
42
DELISTED
Terns Pharmaceuticals
TERN
$15.4M 0.5%
5,576,558
– –
KRRO icon
43
Korro Bio
KRRO
$205M
$15.2M 0.49%
874,614
– –
ORKA
44
Oruka Therapeutics
ORKA
$6.28B
$14.8M 0.48%
1,444,709
+694,709
+93% +$8.66M
DFTX
45
Definium Therapeutics
DFTX
$5.2B
$14.6M 0.47%
2,500,000
-316,594
-11% -$2.27M
UPB
46
Upstream Bio Inc
UPB
$295M
$14.1M 0.46%
2,299,567
+1,299,567
+130% +$12.4M
OLMA icon
47
Olema Pharmaceuticals
OLMA
$846M
$12.9M 0.42%
3,442,833
– –
SEPN
48
Septerna Inc
SEPN
$1.8B
$11.1M 0.36%
1,912,929
– –
NVAX icon
49
Novavax
NVAX
$1.53B
$9.73M 0.32%
1,518,182
-481,818
-24% -$3.98M
HELP
50
Cybin Inc
HELP
$989M
$9.7M 0.31%
1,529,987
– –
1
2
3 4

Similar funds

PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
NP
NorthRock Partners Minneapolis, Minnesota $6.89B AUM 19.83% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return
RCWMU
Rothschild & Co Wealth Management (UK) London, United Kingdom $6.93B AUM 1.4% 1-Year Est. Return
CA
Cambridge Associates Boston, Massachusetts $6.93B AUM 17.96% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
CI
Cincinnati Insurance Fairfield, Ohio $6.94B AUM 20.24% 1-Year Est. Return

Deep Track Capital's Q1 2025 Portfolio in Review

As of Q1 2025, Deep Track Capital held 79 positions worth $3.09B, up 15% from $2.68B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Deep Track Capital deployed $944M of net new capital in Q1 2025, opening 16 new positions and adding to 25 existing holdings. Its largest new stake was Sarepta Therapeutics: 899,731 shares worth $57.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

On the sell side, the largest reduction was Guardant Health, an estimated $42.1M trimmed.

  • Deep Track Capital's largest Q1 2025 buy was Sarepta Therapeutics: 899,731 shares worth $57.4M.
  • Deep Track Capital added most to Ionis Pharmaceuticals in Q1 2025, an estimated $86.1M increase.
  • Deep Track Capital's biggest Q1 2025 reduction was Guardant Health, cutting an estimated $42.1M.
  • Deep Track Capital fully exited SpringWorks Therapeutics in Q1 2025, selling an estimated $125M.
  • Deep Track Capital's ten largest holdings make up 53% of its $3.09B portfolio in Q1 2025.
  • Deep Track Capital opened 16 new positions and closed 10 in Q1 2025.
  • Deep Track Capital's portfolio value rose 15% quarter-over-quarter to $3.09B.

Based on Deep Track Capital's 13F filing for Q1 2025, filed 15 May 2025.